• PDF / 169,295 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 66 Downloads / 152 Views

DOWNLOAD

REPORT

---

1 S

Ventricular arrhythmias following off-label use in COVID-19: 2 case reports In a retrospective cohort study of 91 patients, two patients [ages and sexes not stated] were described, who developed ventricular arrhythmias manifested as classic Torsades de pointes (TdP), polymorphic ventricular tachycardia or ventricular fibrillation during off-label use of azithromycin and hydroxychloroquine for COVID-19. The patients, who were diagnosed with COVID-19, received off-label therapy with azithromycin and hydroxychloroquine [routes and dosages not stated]. The patients developed ventricular arrhythmias manifested as classic TdP with QT prolongation as indicated in a telemetry rhythm strip (ECG) (one patient) and polymorphic ventricular tachycardia (VT) and ventricular fibrillation (VF) (one patient); with severe multisystem disease secondary to COVID-19 in the latter [durations of treatment to reactions onset and outcomes not stated]. Maraj I, et al. Incidence and determinants of QT interval prolongation in COVID-19 patients treated with hydroxychloroquine and azithromycin. Journal of Cardiovascular 803498714 Electrophysiology 31: 1904-1907, No. 8, Aug 2020. Available from: URL: http://doi.org/10.1111/jce.14594

0114-9954/20/1819-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 29 Aug 2020 No. 1819